The study found no mean difference in all-cause healthcare costs for patients with newly diagnosed nonvalvular atrial fibrillation initiating treatment with dabigatran versus warfarin.
Sabyasachi Ghosh, MS
Advertisement
Articles by Sabyasachi Ghosh, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Hidden Reimbursement Crisis in Medicare’s Drug Price Negotiation Program
2
FDA Grants Breakthrough Therapy Designation to Investigational Cannabis-Derived Therapy for Chronic Low Back Pain
3
ADA 2026: Optimized Inhaled Insulin Dosing Outperforms Subcutaneous Analogs for Postprandial Glucose in T1D
4
ADA 2026: Survodutide Cuts Visceral Fat and Normalizes Liver Fat in MASLD. Here's What the Data Mean for Metabolic Risk
5